MEDX ... anybody following? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following?

MEDX 31.58

+1.4%

Nov 5 12:44 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (1783)	7/2/2007 3:00:07 AM
From: Icebrg	of 2240

Maybe Merck/Serono, in one of their post-merger reviews, came to the conclusion that the likely market for this product was not large enough to pursue. Which may not be the case for Genmab, as they are looking for ways to motivate the existence of a US sales organzation. The paper trades on the Copenhagen stock exchange (owned by OMX), but the number of shares mentioned by you seems to be on the low side. I have got a figure of about 34.000 plus shares, which in itself is a very low figure. I don't believe that too much should be made from the return of this product. At present Humax-CD20 and GSK shadows everything else. Medarex has, as a matter of fact, a royalty interest in Humax-CD4, which, depending on sales volumes, could reach into the two-digit domain. Erik

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next